acetylleucine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	71	99-15-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: acetylleucine (S)-2-Acetamido-4-methylpentanoic acid Acetyl-L-leucine N-Acetylleucine	used for treating vestibular-related imbalance and vertigo Molecular weight: 173.21 Formula: C8H15NO3 CLOGP: 0.86 LIPINSKI: 0 HAC: 4 HDO: 2 TPSA: 66.40 ALOGS: -1.20 ROTB: 4

Molecule

Description

Molfile Inchi Smiles

Synonyms:

acetylleucine
(S)-2-Acetamido-4-methylpentanoic acid
Acetyl-L-leucine
N-Acetylleucine

used for treating vestibular-related imbalance and vertigo

Molecular weight: 173.21
Formula: C8H15NO3
CLOGP: 0.86
LIPINSKI: 0
HAC: 4
HDO: 2
TPSA: 66.40
ALOGS: -1.20
ROTB: 4

Drug dosage:

None

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Inappropriate antidiuretic hormone secretion	65.96	52.52	16	386	15446	63473174

Showing 1 to 1 of 1 entries

Previous1Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anticoagulation drug level above therapeutic	75.63	65.72	14	377	2102	34954438

Showing 1 to 1 of 1 entries

Previous1Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatitis acute	67.88	45.75	18	780	15524	79728066
Anticoagulation drug level above therapeutic	63.62	45.75	13	785	3607	79739983
Haematoma	61.11	45.75	22	776	52173	79691417
Inappropriate antidiuretic hormone secretion	50.13	45.75	16	782	26297	79717293

Showing 1 to 4 of 4 entries

Previous1Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	N07CA04	NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS ANTIVERTIGO PREPARATIONS Antivertigo preparations
CHEBI has role	CHEBI:25212	metabolites

Showing 1 to 2 of 2 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.9	acidic
pKa2	13.57	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

Show entries

Search:

ID	Source
005881	NDDF
2375522	RXNORM
5209	INN_ID
70912	PUBCHEM_CID
735136009	SNOMEDCT_US
C0256552	UMLSCUI
C088117	MESH_SUPPLEMENTAL_RECORD_UI
CHEBI:166830	CHEBI
CHEMBL1875805	ChEMBL_ID
CHEMBL56021	ChEMBL_ID

Showing 1 to 10 of 14 entries

Previous1 2Next

Pharmaceutical products:

None